XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer

The purpose of this phase II trial was to determine the efficacy and safety of the XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in the elderly patients with metastatic colorectal cancer (MCRC). A total of 50 patients with MCRC aged ⩾70 years received oxaliplatin 130 mg m(−2) on day...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Feliu, J, Salud, A, Escudero, P, Lopez-Gómez, L, Bolaños, M, Galán, A, Vicent, J-M, Yubero, A, Losa, F, De Castro, J, de Mon, M Á, Casado, E, González-Barón, M
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2006
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361238/
https://ncbi.nlm.nih.gov/pubmed/16552438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603047
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller